Ingenium Therapeutics

Successful Collaboration Between Yale University & Ingenium!

Exciting news from Ingenium Therapeutics! The company has officially partnered with Yale University to advance its CAR-NK-based solid tumor treatment project. This collaboration was selected as part of the Global Industry Technology Cooperation Program, managed by the Korea Institute for Advancement of Technology (KIAT). By integrating Ingenium’s CAR-NK technology with Yale’s nanoparticle drug delivery system, this joint research project is expected to create significant synergies in cancer treatment innovation.

The project will receive KRW 2 billion (approximately $1.5 million) per year in funding for three years. The research will be led by Ingenium, in collaboration with Yale University and KAIST. Depending on research progress, an additional two years of funding may be granted.

The primary objective of this project is to develop the CAR-NK therapy to a preclinical stage, preparing for global out-licensing. This strategic approach is expected to open doors to major international markets, significantly expanding Ingenium’s global footprint.

With this powerful collaboration between Ingenium and Yale, we are excited to see what groundbreaking results emerge. Laplace Partners will continue to monitor the project’s progress and bring you the latest updates.

Visit Ingenium’s Website